» Articles » PMID: 16176171

Alterations of Glycosaminoglycan Metabolism in the Development of Diabetic Complications in Relation to Metabolic Control

Overview
Specialties Biochemistry
Pathology
Date 2005 Sep 24
PMID 16176171
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Disturbed metabolism of glycosaminoglycans (GAGs) has been proposed to play an important role in the pathogenesis of late diabetic complications. The effect of diabetic complications and metabolic control on both total serum GAGs content and the serum activity of lysosomal glycosidases (N-acetyl-beta-D-glucosaminidase, alpha-L-fucosidase, beta-D-galactosidase, and alpha-D-mannosidase) contributing to GAGs degradation, was investigated in 48 patients with type 2 diabetes mellitus. The activity of beta-D-glucosidase and acid phosphatase, the lysosomal enzymes unrelated to GAGs metabolism, was determined for comparison. The elevated serum total GAG concentration in diabetic patients was strongly and positively influenced by poor metabolic compensation of diabetes and the presence of vascular complications. A similar tendency has been shown in regard to the activity of enzymes involved in GAG degradation, especially N-acetyl-beta-D-glucosaminidase, alpha-L-fucosidase and beta-D-galactosidase. Furthermore, the total serum GAG concentrations, as well as the activity of lysosomal enzymes involved in the extracellular matrix degradation, closely followed metabolic compensation, regardless of diabetic vascular complications. Thus, we suggest that increased values of the investigated parameters may indicate the degree of endothelial cell dysfunction and may be useful to predict the development of diabetic vascular pathology.

Citing Articles

Mechanistic evaluation of enhanced graphene toxicity to Bacillus induced by humic acid adsorption.

Zhang X, Zeng J, White J, Li F, Xiong Z, Zhang S Nat Commun. 2025; 16(1):184.

PMID: 39753547 PMC: 11699226. DOI: 10.1038/s41467-024-55270-2.


An At-Risk Population Screening Program for Mucopolysaccharidoses by Measuring Urinary Glycosaminoglycans in Taiwan.

Lin H, Lee C, Lo Y, Tu R, Chang Y, Chang C Diagnostics (Basel). 2019; 9(4).

PMID: 31590383 PMC: 6963841. DOI: 10.3390/diagnostics9040140.


Serum heparan sulfate and chondroitin sulfate concentrations in patients with newly diagnosed exfoliative glaucoma.

Maric V, Bozic M, Cirkovic A, Stankovic S, Marjanovic I, Grgurevic A PeerJ. 2019; 7:e6920.

PMID: 31198625 PMC: 6535222. DOI: 10.7717/peerj.6920.


A selective screening program for the early detection of mucopolysaccharidosis: Results of the FIND project - a 2-year follow-up study.

Colon C, Alvarez J, Castano C, Gutierrez-Solana L, Marquez A, OCallaghan M Medicine (Baltimore). 2017; 96(19):e6887.

PMID: 28489793 PMC: 5428627. DOI: 10.1097/MD.0000000000006887.


Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry.

Kubaski F, Mason R, Nakatomi A, Shintaku H, Xie L, van Vlies N J Inherit Metab Dis. 2016; 40(1):151-158.

PMID: 27718145 PMC: 5203965. DOI: 10.1007/s10545-016-9981-6.